Hey y'all
Tweeting about the clinical year in review 2 session #B1 at #ATS2020 on #Asthma, #Sleep Medicine and occupational lung disease.

No COI to declare

First, up, an excellent session by Dr. Sunita Sharma of @CU_PSCCM on #Asthma (1/n )

Yaghoubi et al. PMID 31166782 pub. in @ATSBlueEditor
$ Uncontrolled asthma -> direct costs $1349/pt-year, indirect $3350/ pt-year, 12% loss in productivity
$ Economic burden highest in HI, lowest in AR
$ ~20% in direct costs with asthma control

#ATS2020 #B1 #MedEd (2/ )

Litonjua et al. PMID 32023372 pub @NEJM
6y f/u analysis of VDAART study
Vit D suppl. to preg mothers 10-18wk preg
not supplemented
No effect on asthma, persist. wheeze, AR, eczema or LRTI at age 6 in child

#ATS2020 #B1 #MedEd (3/ )

Beasley et al. PMID 31112386 pub @NEJM
For Mild asthma:
PRN ICS+LABA superior to PRN SABA & PRN SABA+ICS for severe exac. prevention
maint. ICS superior to PRN ICS+LABA & PRN SABA for symp. control
@ginasthma updated recs to include PRN ICS+LABA

#ATS2020 #B1 (4/ )

Wechsler et al. PMID 31553835 pub @NEJM
For black adults and children with asthma uncont. with ICS alone,
change to ICS/LABA better than ICS dose for adults+adolescents
changes to ICS/LABA = ICS dose in children

#ATS2020 #B1 (5/ )

Holguin et al. PMID 31558662 pub @ERSpublications
To exacerbations in severe asthma, consider:
Tiotropium recommendation
Macrolides
Dupilumab if eosinophilia or oral GC dependent regardless of eos
Need comparision of biologics

#ATS2020 #B1 (6/ )

End of the asthma presentation in session #B1 #ATS2020 (7/ )

#MedEd #MedTwitter #PulmCC #pulmtwitter #asthma

@BCM_Lung @BCM_ALD @bcmhouston @Hananianick @UmaAyyala @DharaniNaren @alapat_phil @KantaVelamuri @sunjaydevarajan @sfaiz212 @virenkaul @Sarah_Assaf20 @udit_chaddha

@BrunoRodrigMD @nomadic_medic @ogarnerccm @cgrazmd